— First and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000 to 9,000 patients in the U.S. 1 — Company expects DAYBUE to be available by the end of April, 2023 — Rare Pediatric Disease Priority Review Voucher granted in connection with approval —
News Category: General
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
Company to host conference call and webcast on Monday, February 27, 2023 , at 4:30 p.m. Eastern Time SAN DIEGO –(BUSINESS WIRE)–Feb. 14, 2023– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2022 financial results on Monday, February
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO –(BUSINESS WIRE)–Feb. 13, 2023– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on February 10, 2023 , the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 310,065 shares of common
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
SAN DIEGO –(BUSINESS WIRE)–Jan. 9, 2023– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Doug Williamson as Executive Vice President, Head of Research and Development (R&D). Dr. Williamson will lead research and development at Acadia and will serve as a member
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics
– Study results consistent across different patient groups, including those in long-term care facilities SAN DIEGO –(BUSINESS WIRE)–Jan. 3, 2023– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the journal Drug Safety published results from a retrospective analysis finding a
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
SAN DIEGO –(BUSINESS WIRE)–Dec. 21, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 , at 9:00 a.m. Pacific Time , followed by a question and answer session.
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
SAN DIEGO –(BUSINESS WIRE)–Nov. 8, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences: Guggenheim 4 th Annual Immunology and Neurology Day November 14, 2022 in New York, NY J.P.
Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic
– Dr. Stankovic to transition to advisory role at year-end SAN DIEGO –(BUSINESS WIRE)–Oct. 27, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that its President, Srdjan (Serge) Stankovic , M.D., M.S.P.H., who is responsible for R&D, and Medical and Scientific functions, will
Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
Company to host conference call and webcast on Wednesday, November 2, 2022 , at 4:30 p.m. Eastern Time SAN DIEGO –(BUSINESS WIRE)–Oct. 20, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2022 financial results on Wednesday, November 2, 2022 ,
Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors
SAN DIEGO –(BUSINESS WIRE)–Oct. 13, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Adora Ndu , Pharm.D., J.D. to its Board of Directors. Dr. Ndu is a biopharma executive with more than 15 years of experience in regulatory affairs and clinical development.